United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $548.69, for a total value of $5,212,555.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,229,077.97. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

United Therapeutics Stock Down 1.2%

Shares of UTHR opened at $543.39 on Friday. The business has a 50-day simple moving average of $561.93 and a two-hundred day simple moving average of $525.46. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The stock has a market cap of $23.07 billion, a price-to-earnings ratio of 20.06, a PEG ratio of 1.81 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm earned $6.63 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post 26.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent analyst reports. Raymond James Financial began coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Royal Bank Of Canada cut their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $619.42.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the business. Pacer Advisors Inc. grew its stake in shares of United Therapeutics by 0.7% in the 1st quarter. Pacer Advisors Inc. now owns 243,545 shares of the biotechnology company’s stock worth $144,417,000 after buying an additional 1,673 shares in the last quarter. Parallel Advisors LLC grew its position in United Therapeutics by 2.8% in the first quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company’s stock worth $626,000 after acquiring an additional 29 shares in the last quarter. NewEdge Advisors LLC increased its stake in United Therapeutics by 24.7% during the first quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company’s stock worth $1,283,000 after acquiring an additional 428 shares during the last quarter. Janus Henderson Group PLC raised its position in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the period. Finally, Bull Harbor Capital LLC bought a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $494,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.